Glooko acquires Monarch Medical to expand into inpatient diabetes care

Glooko acquires Monarch Medical: ©Glooko/Monarch Medical

Glooko Inc., a provider of remote patient monitoring and digital health solutions for diabetes, announced it has acquired Monarch Medical Technologies, developer of the EndoTool Glucose Management System.

The deal extends Glooko’s reach from outpatient diabetes care into inpatient glycemic management, an area where 30% to 40% of hospitalized patients require insulin therapy. Terms of the acquisition were not disclosed.

“This acquisition represents a pivotal step in Glooko’s mission to transform diabetes management in every care setting,” said Mike Alvarez, chief executive officer of Glooko, in a statement. “By adding Monarch’s proven inpatient insulin dosing expertise, we’re now uniquely positioned to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety.”

EndoTool, which has FDA clearance, uses a patient-specific algorithm to help clinicians optimize insulin dosing for hospitalized patients. The company said the platform reduces the risk of hypoglycemia while helping hospitals meet federal quality standards and improving clinical workflows.

“Effective glycemic management doesn’t begin or end at the hospital doors. It’s a continuous journey,” said Mark Clements, chief medical and strategy officer at Glooko. “By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions, help hospitals meet quality requirements, and deliver measurable improvements in patient outcomes across the continuum.”

Glooko’s platform, used by millions of patients and more than 8,000 clinics worldwide, aggregates data from more than 200 connected devices including glucose monitors, insulin pumps and continuous glucose monitors. The company said adding EndoTool will allow it to support both acute care settings and ongoing outpatient management, aiming to reduce hospital readmissions and improve continuity of care.

The acquisition follows Glooko’s $100 million Series F financing round completed in October 2024, led by Georgian and joined by several other investors. At that time, the company said it planned to pursue growth through product development and acquisitions.

For now, Glooko and Monarch will continue operating their platforms separately, with plans to integrate them into a single system over time.